Moving to Value Unscripted

The episode is meaningfully dense by podcast standards, with specific mechanisms (angiotensin 2, AMPK switch, epigenetic memory), named trials, and concrete cost figures delivered at speed. The B2B-relevant content (employer self-insurance, worksite clinic ROI, the 'lipstick on a pig' VBC critique) is real and non-obvious, though a substantial portion is medical lecture that only partially translates to operator-level insight.

“if you have had a heart attack after five years, compared with the care that most people get, you're 12 times as likely to still be alive. That's nuts. Crazy. I mean, 12 times. Every American should be very concerned that that information's been in the literature for 20 years and not a thing's being done about it”

“they reduce costs by half. Uh, hospitalizations were 1/5, ER visits were 1 third”

The reframing of specific drugs as cell/organ protectors rather than risk-factor lowerers (citing Milton Packer) and the epigenetic memory explanation for why the Steno 2 Kaplan-Meier curves kept diverging after switching all patients to optimal therapy are genuinely fresh clinical arguments. The employer/system critique and Singapore/Germany comparisons, however, are well-worn in value-based care circles.

“we should start thinking about Jardiance and these other six drugs not as risk factor lowering drugs, but as drugs that protect cells and organs”

“The curve didn't change at all... Half the usual care people were dead at age 68... the answer there, I think, is there's a point of no return when you start making angiotensin 2 and aldosterone”

Bestermann is a genuine 50-year practitioner who has implemented these protocols in the field, worked as senior clinical advisor at a major payer, and has real worksite-clinic outcome data - not a conference-circuit thought leader. His depth is earned, though he is relatively unknown outside niche preventive cardiology circles and the episode does not fully exploit his payer-side experience.

“When I was working with a big insurance company, you saw that kind of performance, I mean 14%, 20%, 22%, but then we had people get up to 65% percent by the time we were done”

“I've actually worked with a worksite clinic in southwest Louisiana. These doctors were great. They worked with us to produce what we're talking about. They reduce costs by half”

The episode is unusually specific: named studies (Steno 2, ACCORD, Framingham), named drugs with mechanisms (losartan, eplerenone, metformin, empagliflozin), named researchers (Peter Libby, Milton Packer, Fuster), concrete dollar figures ($60/month vs. $1,300, $720/year vs. $26,000/year), and measurable worksite outcomes - this is well above average for a healthcare podcast.

“the modern medical uh, treatment is approximately $26,000 a year. The optimal medical uh, therapy that you promote is roughly $720”

“By 2008, the study had been in play for 13 years. There were one fourth as many heart attacks, a fifth as many strokes, the sixth as many people went on dialysis, a third as many people went blind, uh, third as many people had amputations”

Several hosts ask substantive questions - Kim Lynch's direct challenge about the revenue hole hospitals would face and her 'lipstick on a pig' diagnostic test question are genuinely sharp; Donovan Pyle grounds the conversation in published cost figures from Bestermann's own article. However, major claims (the 12x survival figure, the GLP-1 cost doubling assertion) go unchallenged, and the tone is predominantly reverential rather than interrogative.

“Do you have a sense of what kind of hole that creates? What percentage of a hole does that create in their revenue? Right. Is this they're going from, you know, whatever last year was. If you do this, you're going to see a 50% hole”

“how if you are a clinician listening to this or even an administrator who gets approached with a program, do you have a couple of tells of uh, this is the real, real... or. Nope, this is just another lipstick on a pig”